Immunic, Inc. reported positive data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium, in patients with moderate-to-severe ulcerative colitis .
Immunic, Inc. reported positive data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium, in patients with moderate-to-severe ulcerative colitis .